Asahi Life Asset Management CO. LTD. Sells 160 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Asahi Life Asset Management CO. LTD. lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.1% in the 2nd quarter, Holdings Channel reports. The firm owned 1,280 shares of the biopharmaceutical company’s stock after selling 160 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in Alnylam Pharmaceuticals were worth $417,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock valued at $475,353,000 after purchasing an additional 156,411 shares during the last quarter. Finally, Orbis Allan Gray Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 11.0% during the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after purchasing an additional 162,121 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $434.56 on Thursday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The firm has a market capitalization of $57.41 billion, a P/E ratio of -175.94 and a beta of 0.30. The company’s 50-day moving average is $459.06 and its 200 day moving average is $374.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $1.25 billion for the quarter, compared to analyst estimates of $943.37 million. During the same period in the prior year, the company posted ($0.50) EPS. The firm’s revenue for the quarter was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This represents a 12.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Evercore ISI increased their price objective on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a report on Thursday, September 11th. Jefferies Financial Group lowered their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Finally, The Goldman Sachs Group increased their price target on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $478.67.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.